Literature DB >> 7493025

Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy.

H Watkins1, D Conner, L Thierfelder, J A Jarcho, C MacRae, W J McKenna, B J Maron, J G Seidman, C E Seidman.   

Abstract

Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disorder manifesting as cardiac hypertrophy with myocyte disarray and an increased risk of sudden death. Mutations in five different loci cause FHC and 3 disease genes have been identified: beta cardiac myosin heavy chain, alpha tropomyosin and cardiac troponin T. Because these genes encode contractile proteins, other FHC loci are predicted also to encode sarcomere components. Two further FHC loci have been mapped to chromosomes 11p13-q13 (CMH4, ref. 6) and 7q3 (ref. 7). The gene encoding the cardiac isoform of myosin binding protein-C (cardiac MyBP-C) has recently been assigned to chromosome 11p11.2 and proposed as a candidate FHC gene. Cardiac MyBP-C is arrayed transversely in sarcomere A-bands and binds myosin heavy chain in thick filaments and titin in elastic filaments. Phosphorylation of MyBP-C appears to modulate contraction. We report that cardiac MyBP-C is genetically linked to CMH4 and demonstrate a splice donor mutation in one family with FHC and a duplication mutation in a second. Both mutations are predicted to disrupt the high affinity, C-terminal, myosin-binding domain of cardiac MyBP-C. These findings define cardiac MyBP-C mutations as the cause of FHC on chromosome 11p and reaffirm that FHC is a disease of the sarcomere.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493025     DOI: 10.1038/ng1295-434

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  159 in total

1.  Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy.

Authors:  K Prasad; J Atherton; G C Smith; W J McKenna; M P Frenneaux; P Nihoyannopoulos
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

2.  On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture.

Authors:  A J Marian
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

Review 3.  Modifier genes for hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Curr Opin Cardiol       Date:  2002-05       Impact factor: 2.161

Review 4.  Athlete"s heart and hypertrophic cardiomyopathy.

Authors:  A Pelliccia
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

5.  Experimental Modeling Supports a Role for MyBP-HL as a Novel Myofilament Component in Arrhythmia and Dilated Cardiomyopathy.

Authors:  David Y Barefield; Megan J Puckelwartz; Ellis Y Kim; Lisa D Wilsbacher; Andy H Vo; Emily A Waters; Judy U Earley; Michele Hadhazy; Lisa Dellefave-Castillo; Lorenzo L Pesce; Elizabeth M McNally
Journal:  Circulation       Date:  2017-08-04       Impact factor: 29.690

Review 6.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

7.  To screen or not is not the question--it is when and how to screen.

Authors:  A J Marian; R Roberts
Journal:  Circulation       Date:  2003-05-06       Impact factor: 29.690

Review 8.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 9.  MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation.

Authors:  Diederik W D Kuster; Sakthivel Sadayappan
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

10.  Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.

Authors:  Diederik W D Kuster; Thomas L Lynch; David Y Barefield; Mayandi Sivaguru; Gina Kuffel; Michael J Zilliox; Kyoung Hwan Lee; Roger Craig; Rajasekaran Namakkal-Soorappan; Sakthivel Sadayappan
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.